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Sammendrag 
Bakgrunn: Sykefraværet i Norge er høyt, til tross for bedring i nøkkelindikatorer på 
folkehelse. Attraksjons- og utstøtingsmodellen tilskriver det høye sykefraværet til henholdsvis 
valg kontra tvang. Omtrent 80 % av vurderinger av pasienters arbeidsevne er utført av 
fastleger, og for en fastlege involverer dette en balanse mellom rollen som portvokter og 
rollen som pasientens advokat. Fastleger rapporterer ubehag i portvokter-rollen, blant annet 
da vurderinger av pasienters arbeidsevne oppleves som en tvetydig oppgave. Denne 
vurderingen antas å avhenge av legers-, pasienters- og samfunnets- terskel for å være «syk» 
og å være «frisk». Vi foreslår at denne terskelen vil kunne være avhengig av endringer i 
befolkningens holdninger over tid. Målet med denne studien å undersøke om det er en økning 
i varigheten av langtidssykefraværet i Norge fra 1994 til 2007. 
Metode: FD-trygd er et administrativt generert register med longitudinelle forløpsdata 
på hele den norske befolkningen fra 1992 og utover. Vi testet først en hypotese på fire a-priori 
utvalgte diagnostiske kategorier, som alle er karakterisert av blant annet en brå og lett 
observerbar inntreden. Deretter undersøkte vi utviklingen av varigheten av langtidssykefravær 
i Norge for alle diagnostiske kapitler i ICPC-2. 
Resultater: Gjennomsnittlig langtidssykefravær i Norge øker i perioden 1994 til 2007. 
Resultatene er robuste, og økningen fremtrer i våre utvalgte diagnoser, i majoriteten av alle 
diagnostiske kapitler i ICPC-2, for begge kjønn, i alle utdanningsgrupper og i de fleste 
aldersgrupper. Samlet indikerer resultatene at den gjennomsnittlige varighet av sykefravær 
øker med 1.5 kalenderdager per år i perioden 1994 til 2007. Videre finner vi også en økning i 
forekomsten av sykefraværsepisoder. Den generelle økningen i sykefraværet kan tilskrives en 
økning i både varighet- og økning i forekomst av sykefraværsepisoder.  
Konklusjon: Den sterke og konsistente økningen i sykefraværsvarighet kan være et 
resultat av endringer i terskelen for å iverksette og avslutte en sykefraværsepisode. Denne 
terskelen antas å være avhengig-, og påvirket av, gradvise endringer i befolkningens 
 v 
holdninger. Vi foreslår at den observerte utviklingen i varighet av sykefraværet påvirkes av en 
senkning av denne grensen. 
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Abstract 
Background: Sickness absence in Norway is high despite improvements in key 
indicators of public health. The pull and the push models attribute the high levels of sickness 
absence to choice vs. coercion, respectively. Approximately 80% of assessments regarding 
patients’ work ability are performed by GPs, and this involves balancing the role as a 
gatekeeper with the role as the patients’ advocate. GPs report being uncomfortable with this 
gatekeeping role, partly due to the ambiguousness associated with work ability assessments. 
These assessments are assumed to be dependent on the threshold for being “sick” or “healthy, 
whether determined at a GP, patient, or societal level. We suggest that this threshold may be 
subject to changes in the population’s attitudes over time. The aim of this study is to 
investigate if there is an increase in the duration of long-term sickness absence in Norway 
from 1994 to 2007. 
Methods: FD-insurance is an administratively generated registry, containing 
longitudinal data on the entire Norwegian population from 1992 and onwards. We first tested 
a hypothesis on four a-priori selected diagnostic categories from ICPC-2, characterized by an 
abrupt and overt onset. Secondly, we explored the development of the duration of long-term 
sickness absence for all ICPC-2 diagnostic chapters. 
Results: There is an increase in mean duration of long-term sickness absence from 
1994 to 2007. The findings are robust, being observed in our selected diagnoses, the majority 
of all ICPC-2 diagnostic chapters, for both genders, in all educational groups, and in almost 
every age group. On average, the duration of sickness absence is prolonged by 1.5 calendar 
days per year from 1994 to 2007. There is also an increase in prevalence of sickness absence 
episodes. The general increase in sickness absence can be attributed to an increase in both 
duration and prevalence of sickness absence episodes. 
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Conclusion: The strong and consistent increase in duration of sickness absence might 
be a result of changes in the threshold for initiating and terminating a sickness absence 
episode. This threshold is presumed to be dependent on, and subject to, gradual changes in 
attitudes in the population. We suggest that the observed development in duration of sickness 
absence is affected by an increase in the threshold for terminating a sickness absence episode, 
and a lowering of the threshold for initiating a sickness absence episode.  
 
Keywords 
Sickness absence, sick leave, moral hazard, attitudes, threshold, push, pull, registry data, 
Norway 
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Background 
High levels of sickness absence in the Norwegian population 
Sickness absence levels in Norway are high [1], doubling the average sickness absence 
levels in the other OECD countries [2]. The cumulative development of sickness absence 
within Norway has fluctuated during recent decades with a strong increase from mid 1990s to 
2001, followed by an abrupt decrease from 2003-2005, and a stabile increase from 2005 and 
onwards [1, 3]. The sickness absence rates per year is higher for women compared to men [4] 
and the increasing levels are considered a public health concern, and a challenge with regards 
to the sustainability of the Norwegian welfare state [5]. 
Improvements in public health 
Parallel to the increase in sickness absence levels, there has been a continuous 
improvement in the Norwegian population’s health [1, 6]. Thus the sickness absence levels 
have been viewed as a paradox, as the high levels of sickness absence and the inflow to 
disability benefits, persist in spite of improvements in key indicators in public health [2], such 
as increased life expectancy, decreased child mortality [7], stabile incidence of mental 
illnesses [8] and unchanged self reported perception of personal health status [9]. This 
paradox has led to a strengthening of hypotheses claiming that a potential cause of the high 
levels of sickness absence might be a change in the population’s attitudes towards sickness 
absence [10]. Common mental disorders and musculoskeletal pain compose the main 
diagnostic categories warranting sickness absence [1, 11-13]. These conditions are highly 
prevalent in the population, and more often than not, individuals experience these conditions 
without this resulting in sickness absence [13]. The notion of this in combination with the 
previously mentioned paradox has led experts to emphasize a distinction between causes of 
sickness and causes of sickness absence [13]. Hence, pointing to a discrepancy between 
sickness in a population and sickness absence in a population.  
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The pull and the push models 
The pull and the push models offer competing explanations for the high levels of 
sickness absence. Originating from economical sciences [14] the pull model considers 
individuals as rational agents, where behavior is directed by consumer incentives and 
available information [15]. In this view, when facing various courses of action, individuals 
will be predisposed to make choices that maximize their own benefit [16]. Hence, sickness 
absence is understood as a result of an individual’s rational choices, with these choices being 
affected by different economic incentives and not simply ill health per se. This phenomenon 
is called moral hazard [17]. On this note, the pull model argues that absenteeism from work is 
affected by generosity in welfare programs [18]: the higher the replacement of income during 
sickness absence, the higher the likelihood of initiating a sickness absence episode [15]. Any 
transition from employment to sickness benefits is within the understanding of this scope 
attributed to rational choice [16]. With the welfare state reimbursing 100% of lost income in 
the case of sickness absence, the pull model would argue that individuals might easily be 
inclined to choose to stay home with 100% salary instead of receiving the exact same amount 
of money while at work. 
The push model is founded in sociology and social sciences. According to the push 
model, sickness absence is an involuntary consequence of forces residing outside of an 
individual’s control. Typically, social differences and inequalities [14, 19], like gender 
differences [19], low socioeconomic status and low education [20] are highlighted as main 
contributing risk factors to sickness absence. In addition, increased workplace brutality [14, 
21], exposure to stress and exceedingly higher demands at an increased number of arenas 
[14], reduced perception of workplace control [20] and health compromising consequences of 
labor-market conditions, are suggested as other contributing risk factors to sickness absence. 
From this perspective, generous levels of sickness benefits could be understood as a 
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contributor to a more excluding work life, by attracting recipients and forcing them over in 
more permanent disability benefits [22]. 
The main difference between the pull and the push model can be summarized into a 
different weighting of choice vs. coercion, with regards to the processes underlying sickness 
absence. According to the pull model, effective sickness absence management would be 
dependent on an increased public control over employees claiming sickness benefits, or a 
reduced economic compensation trough the Norwegian sickness insurance scheme. If 
following the rationale from the push model, public initiatives in sickness absence 
management would focus on reducing any cause of expulsion from the workforce. The 
Including Workforce Agreement [1], initiated in 2001 is based on the push perspective; by 
encouraging increased participation and collaboration between GPs, employers and sick listed 
employees, the Including Workforce Agreement strives to facilitate a speedy return to work 
for sick listed individuals.  
The Norwegian sickness insurance scheme 
The Norwegian sickness insurance scheme recompenses 100% of the employees’ lost 
income due to work absence in the event of temporary illness [23] with benefits starting the 
first day of the sickness absence. The documentation of illness/injury needs certification from 
a GP when sickness absence exceeds a three-day period. Sickness benefits are issued for a 
period of one calendar year (365 calendar days = 248 workdays), with the first 16 workdays 
covered by the employer, and the remaining workdays covered by the Norwegian sickness 
insurance scheme. No western countries offer such a high degree of compensation. After one 
calendar year, sickness benefits are terminated, leaving the sick listed individual with a 
possibility to apply for a transition to more permanent benefits, like disability pension and 
unemployment benefits. The amount of income being reimbursed is related to the basic 
amount (B.a.). B.a. is the basic monetary unit used in the pension system, and this amount is 
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adjusted yearly in accordance with the development of average wages. In 2010 the B.a. was 
NOK 74 721 [4]. The maximum mandatory reimbursement rate in sickness benefits over a 
one-year period is 6 B.a. [24].  
Policies and interventions for sick listing in Norway have remained mainly unchanged 
from 1994 to 2007, with the exception being an intervention facilitating use of graded 
sickness absence (2004), the including workforce program (2001) and a 1998 reform, 
increasing the number of sick days reimbursed by employers from 14 to 16 days. In 2001 the 
government also introduced the general practitioner scheme providing all citizens with a 
permanent general practitioner (GP) through a publicly controlled patient list system [25].  
Besides these changes, the major structure of the Norwegian sickness insurance scheme, such 
as the degree of income compensation and the public management of the sickness insurance 
scheme, has been unchanged from 1994 to 2007.  
The Norwegian primary health care system 
The GPs in the general practitioner scheme are self-employed, receiving 30% of their 
income from a per-capita-based-fee from their patient list, and the remaining 70% from 
consultation fees reimbursed by patient fees and funding from the Norwegian sickness 
insurance scheme [25]. Medical consultations regarding sickness certification are frequent 
[26], and approximately 80% of assessments of a patient’s function with regards to work 
ability are done by GPs in the patient list system [2]. A GPs mandate and responsibility 
involves balancing the role of advocating the patients’ rights in relation to their health related 
problems and rights to social welfare, as well as effectively restricting public access to 
welfare benefits, to assure a sustainable functioning of the welfare state [27]. This bipartite 
role is referred to as “gatekeeping”. GPs report being uncomfortable with the gatekeeping role 
[28, 29], and when forced to choose, GPs more often act in accordance with what they 
perceive as being in the interest of their patients than in the interest of the society [25, 30]. 
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Studies have indicated that the structural and organizational aspects in the patient list system 
might have led to a weakening of the GPs gatekeeping as this scheme provides GPs with 
economic incentives to keep their patients happy, and therefore staying at their patient list 
[25]. The main reason for the GPs’ discomfort in relation to sickness certifications is reported 
to be frequent conflicts with patients claiming sickness certification without eligible medical 
reasons [31, 32] and a general difficulty assessing patients’ work ability and optimal duration 
of a sick spell [26, 31, 33].   
Sickness absence: Threshold decisions on health continuums  
Effective assessment of work ability is affected by the given diagnosis verifiability. 
“Verifiability” can be defined as “to what extent the medical assessment is based on objective 
criteria versus on information from the patient” [34]. A study of a representative sample of 
GPs in Norway, find that the diagnoses that most commonly trigger benefits like 
musculoskeletal pain and common mental disorders [34, 35], are also among the diagnoses 
that GPs find least verifiable [34, 35]. These diagnoses are largely based on the patients’ 
subjective symptom descriptions, rather than on more objective medical criteria [34].  
Assessing the degree of disability is an ambiguous task whether performed 
subjectively or by a physician. We suggest that the nature of disability, whether temporary or 
permanent, cannot be reduced to a healthy-sick dichotomy as almost all health problems and 
illnesses are located on a continuum ranging from healthy to sick. Although some diagnoses, 
such as orthopedic fractures, have a clear dichotomous onset, both the recovery and the 
severity of the fracture will vary on a continuum. Following this argument, subjective 
evaluation of current health status in relation to e.g. illness and work capacity will depend on 
the physicians’ and the patients’ threshold for “being healthy” or “being sick”. We argue that 
this threshold may be dependent on and subject to gradual changes in attitudes of the 
population.  
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 We propose that both the physicians’ and the patients’ threshold for initiating sickness 
absence are lower in ambiguous medical assessments with limited access to overt measures of 
health. Presumably, the threshold for terminating sickness absence is also higher in these 
cases. However, a previous study reporting on trends in duration for sickness absence, finds 
that duration of sickness absence for fractures, dislocations and sprains, has increased [10]. 
These findings might indicate that our concern regarding a decreased and increased threshold 
for initiating and terminating a sickness absence episode not only arises in relation to 
ambiguous diagnoses, but also for a wider range of diagnoses.  
In sum, sickness absence in Norway is high [1, 2] despite improvements in key 
indicators of public health. The pull and the push models attribute the high levels of sickness 
absence to choice vs. coercion, respectively. Approximately 80% of assessments of patients’ 
function with regards to work ability are performed by GPs in the patient list system, and 
from a GPs perspective this involves balancing the role as a gatekeeper with the role of the 
patient’s advocate. GPs report being uncomfortable with the gatekeeping role, as assessing the 
degree of work ability is an ambiguous task. This assessment is assumed to be dependent on 
the threshold for being “sick” or “healthy”, whether residing at a GP, patient, or societal level.   
The aim of this study is to investigate if there is an increase in the duration of long-
term sickness absence in Norway from 1994 to 2007. In this study long-term sickness absence 
is defined as sickness absence exceeding 16 workdays, hence sickness absence covered by the 
Norwegian sickness insurance scheme. We hypothesize that the duration of long-term 
sickness absence has increased over the time period in question. To test this hypothesis, we 
selected four diagnostic categories a-priori originating from the main diagnostic manual 
employed by Norwegian physicians and general practitioners: the International Classification 
of Primary Care, second edition (ICPC-2). Aspiring to avoid potential threshold issues, the 
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selected diagnoses are characterized by an abrupt and overt onset. Following the hypothesis 
testing we explored if a similar increase were found in the other ICPC-2 diagnostic chapters. 
Methods 
Definitions and clarifications 
For the purpose of this study the term “sickness absence” refers to 100% sickness 
absence only, and does not include other variations of sickness absence such as graded- or 
active sickness absence. We define “duration” as mean duration of long-term sickness 
absence episodes covered by the Norwegian sickness insurance scheme, thus excluding the 
initial 16 workdays covered by the employer. We understand “workdays” as 5 days per week, 
while “calendar days” are defined as 7 days per week. Similarly a work year (248 days) is 
understood as a calendar year (365 days) minus weekends and official holidays.  
Data material 
FD-insurance is a historical event database, collected- and prepared for research by the 
state agencies Statistics Norway, the Norwegian Labor and Welfare Organization and the 
Department of Taxation. FD-insurance is an administratively generated registry, containing 
longitudinal data on the entire Norwegian population from 1992 and onwards. The 
registrations in FD-insurance are at an individual event level, containing high-resolution 
information on e.g. demographics, social security, employment, income, pension and benefits. 
Thus, FD-insurance can be combined into event histories providing a lucid overview of 
transitions in the life of single individuals, the entire population or sub-groups of the 
population [36]. The registry also includes diagnosis-specific information regarding the cause 
of individual sick-spells, and has unchanged routines for data- collection and storage during 
the studied time period. Population documentation of the scale represented in FD-insurance 
and sensitive data collection over time, is possible due to a high degree of trust between the 
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Norwegian population and its government. Furthermore, the Norwegian health care system 
facilitates national data collection due to the publicly controlled management of the general 
practitioners scheme. The information in FD-insurance is of high quality, but unfortunately 
due to the registry’s complicated structure it is underutilized in research [16]. During the 
studied time period there is an increase in the populations mean age, percentage of women in 
the workforce and the percentage of employees with education exceeding high school (Table 
1). 
Selected diagnoses for testing the hypothesis 
The studied diagnoses originate from the main diagnostic manual employed by 
Norwegian physicians and general practitioners; the International Classification of Primary 
Care, second edition (ICPC-2) [24]. The ICPC classification system was updated to ICPC-2 in 
1998 but the revisions did not affect aspects of relevance for this study. To test our 
hypothesis, relevant diagnoses were selected based on a-priori criteria. As a prerequisite the 
selected diagnoses 1) occur with stabile prevalence from 1994 to 2007, 2) have an abrupt 
onset with a distinct transition from “healthy” to “sick/injured”, 3) often require sickness 
absence longer than 16 workdays, 4) occur in the working population, and finally 5) are not 
subject to major changes in treatment from 1994 to 2007. Based on these criteria diagnoses 
affecting different organ systems were selected: fractures, dislocations and sprains; stroke and 
acute myocardial infarction; appendicitis; and finally, concussion. These diagnoses where 
further grouped into 1) orthopedic diagnoses, 2) cardiovascular diagnoses, 3) appendicitis, 
and 4) concussion.  
Ideally, our selected diagnoses should not be subject to substantial changes in 
prevention and treatment procedures, but as it turned out, accommodating this criterion 
proved more difficult than first anticipated. Treatment or prevention for all selected diagnoses 
has undergone changes during the period of interest, with advances in both surgical and 
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pharmacological treatment.  
Study population  
The target population for this study is full-time employees in the Norwegian 
population, aged 18 to 67 (Table 1). Our analysis is based on income-information from the 
working population only, thus excluding information from recipients of e.g. disability 
benefits. To target full-time employees, people with income below 3.5. B.a. were excluded 
from the analysis, with the remaining dataset comprising > 50 % of the entire working age 
population. In 2005, 3.5 B.a. was equivalent to NOK 212,446. In comparison, the 2005 
minimum wages for auxiliary nurses were NOK 276,768 per year, while minimum wages for 
teachers were NOK 340,000 [37]. Employees younger than 18 years, or older than 67 were 
excluded. Since sickness benefits are terminated after one calendar year, sickness absence 
exceeding 248 workdays was excluded from the analysis. Individuals with missing data with 
regards to education or income, and sickness absence episodes with variations in degree, such 
as graded- or active sickness absence were also excluded. After these exclusion criteria, the 
remaining dataset describes data on 20,264,582 individuals in total, accumulated in the period 
1994 to 2007. In sum, the studied population covers > 50 % of the total Norwegian population 
aging between 18 and 67.  
Data management and analysis 
Using STATA/IC 12.0 [38], relevant data was extracted from the FD-insurance 
datasets with the resulting dataset comprising information about 100% sickness absence for 
Norwegian full-time employees, aged 18-67. Episodes registered with overlapping dates and 
diagnoses were merged to ensure correct length of individual sickness absence episodes. 
Episodes ranging from one year to another, were registered at the year of initiation; e.g. 
episodes ranging from December 1995 to January 1996, were registered as episodes in 1995. 
Adjustments were made to accommodate the changes associated with the 1998 reform, where 
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the number of sick days reimbursed by employers was increased from 14 to 16 workdays. 
More specifically, we subtracted two workdays from sickness absence records registered after 
April 1st, 1998. Finally, mean durations of sickness absence were converted from workdays to 
calendar days, with all results presented in calendar days (365 days per year). 
The prevalence for our selected diagnosis groups, as well as total prevalence of all 
sickness episodes adjusted for population size, was calculated using STATA/IC 12.0. 
Regression coefficients (β) describing any change in prevalence per year were calculated 
using SPSS 19. Next, we calculated the mean duration of sickness absence for 1) each of our 
selected diagnoses, 2) the total sickness absence, as well as for 3) each of the individual 
diagnostic chapters in ICPC-2. Both prevalence and mean duration was stratified by gender, 
educational level and age. The stratifications were performed on 1) each of our selected 
diagnoses, 2) the total sickness absence, as well as for 3) each of the individual diagnostic 
chapters in ICPC-2. Regression coefficients (β) describing any change in mean duration of 
sickness absence per calendar year were calculated using SPSS 19. Standard deviations and p-
values were considered to be unwarranted, since the analysis is based on the entire full-time 
work stock of Norway.  
To calculate how prevalence, frequency and duration contribute to the increase in 
sickness absence, we calculated the prevalence of sickness absence episodes per work year. 
The prevalence was separated into two groups, with duration over and under eight calendar 
weeks, respectively. The sickness absence rate can be written as the product of the fraction of 
workers with sickness absence (W), the mean number of sickness absence spells per worker 
with sickness absence episodes (S) and finally the mean duration of each of these episodes 
(D). Using the logarithmic approximation of a growth rate 1
1
1 ln tt t
t
YY Y Y− −
" #− ≈ % &
' (  
we 
decomposed the relative contribution of each of the previously mentioned factors to the total 
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change in the sickness absence rate. The relative contribution of each of the factors can be 
written as follows: 
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Results 
Based on registered sickness absence episodes from 20,264,582 individuals 
accumulated during the period 1994 to 2007, we found an increase in mean duration of long-
term sickness absence. This increase was observed for the a-priori selected diagnostic 
categories except for cardiovascular diagnoses, and also across all diagnostic chapters in 
ICPC-2. Overall, sickness absence was prolonged by 1,5 calendar day per year from 1994 to 
2007. These results will be described in more detail below.  
The prevalence of the a-priori selected diagnoses was stable over the studied time 
period (Table 2). With “prevalence” we understand the number of registered sickness absence 
episodes per year, as reported in FD-insurance. When adjusted for size of the studied 
population, we find that the orthopedic diagnoses, cardiovascular diagnoses, concussion and 
appendicitis do not have a substantial increase in prevalence. When combining sickness 
absence episodes from all diagnostic chapters in ICPC-2 and adjusting for population size, 
there is a 3% yearly increase in prevalence during the studied time period (Table 2). 
Testing the hypothesis applying four selected diagnostic categories 
There was an increase in duration of sickness absence for the selected diagnoses 
(Figure 1 and Table 3). The duration of sickness absence for selected orthopedic diagnoses, 
appendicitis and concussion increased by 1.4, 0.7 and 2.7 calendar days per year, respectively. 
On the other hand, the duration of sickness absence for selected cardiovascular diagnoses was 
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almost stabile with a weak negative trend of - 0.1 days per calendar year.  
Exploratory analysis across all ICPC-2 diagnostic chapters  
The duration of total sickness absence increased by 1.5 calendar days per year from 
1994 to 2007 (Table 3). This increase was observed for sickness absence related to most 
diagnostic chapters in ICPC-2 (Figure 2 and Table 3) except for the chapters N-Neurological 
and K-Cardiovascular, in which duration of sickness absence had a weak decrease or 
stagnated, respectively. It is important to note that the ICPC-2 chapter K-Cardiovascular, is 
comprised of 41 different symptoms, infections, neoplasms, injuries and congenital 
anomalies, and should not be misinterpreted as the two diagnoses comprising the selected 
cardiovascular diagnoses. 
Analyses of robustness of findings: Stratifications for gender, education and age  
The increase in duration of sickness absence for our selected diagnoses was slightly 
higher for women compared to men (Table 3). However, the increase in duration of sickness 
absence was slightly higher for men compared to women when combining sickness absence 
episodes from all diagnostic chapters in ICPC-2. The gender difference in duration of sickness 
absence varies to a large extent between the different diagnostic chapters in ICPC-2.  
The increase in duration of sickness absence could not be attributed to one educational 
stratum especially (Table 3). The strongest increase in duration of sickness absence was found 
in the group with education similar to elementary school, with a yearly increase of 1.9 
calendar days. Similarly, the increase in duration of sickness absence for individuals with 
education equivalent to high school, or education exceeding Bachelor’s degree increased with 
1.7 and 1.3 calendar days, respectively. With two exceptions, the highest increase in duration 
of sickness absence was found in the group with education similar to elementary school. 
These findings were consistent across all ICPC-2 diagnostic chapters, and for the selected 
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diagnoses. 
The increase in duration of sickness absence could not be attributed to any particular 
age group (Table 3). The lowest increase in duration of sickness absence was found in the two 
oldest age groups, and in the oldest age group (> 59) the duration of sickness absence 
decreased by approximately one calendar day per year. These findings were observed in all 
ICPC-2 diagnostic chapters, and for the selected diagnoses. 
In sum, the increase in duration of sickness absence was robust when stratified for 
gender, educational level and age. The increase in duration of sickness absence was most 
prominent for 1) men, 2) individuals with lower levels of education and 3) individuals 
younger than 50 years.  
What contributes to the general levels of sickness absence in Norway from 1994 to 2007? 
Besides the increase in duration of sickness absence, there was also an increase in 
prevalence of sickness episodes per work year. The prevalence increased for 1) sickness 
absence episodes with duration over 8 calendar weeks, and for 2) sickness absence episodes 
with duration less than 8 calendar weeks (Figure 3). The increase in prevalence of sickness 
absence episodes contributed 64.4 % to the development of total sickness absence over the 
course of the study, while the increase in duration contributed 32.8 % to the increase. The 
increase in frequency of sickness absence episodes for the same individual contributed 2.8 % 
to the increase.  
Discussion 
Key findings 
There was an increase in duration of long-term sickness absence from 1994 to 2007, in 
which mean duration of sickness absence episodes increased by 1.5 calendar days per year 
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during the period of interest. This increase was observed in our selected diagnoses and in the 
majority of all ICPC-2 diagnostic chapters. The increase in duration of sickness absence is 
observed for both genders, in all educational groups and in all age groups younger than 60 
years. Moreover, there was also an increase in prevalence of sickness absence episodes with 
duration both over and under eight weeks. The general increase in sickness absence could be 
attributed to an increase in both duration of sickness absence episodes and prevalence of 
sickness absence episodes. 
To the best of our knowledge, there has only been one previous study addressing the 
duration of sickness absence in Norway for a prolonged period of time similar to the time 
span in our study [10]. However, this Norwegian study included only orthopedic diagnoses 
and was based on a dataset with a lower data resolution compared to the data in FD-insurance. 
Their analyses were based on numbers extracted from the Labor Force Survey, the sickness 
benefit registry and the employee/employer registry. These are independent and unrelated 
sources of information, and in comparison, the data in FD-insurance are more elaborately 
processed. 
The majority of studies regarding sickness absence in the Norwegian population have 
traditionally focused on the aggregated number of compensated days in relation to sickness 
absence. Hence, our study offers a complementary perspective to the existing literature on 
sickness absence, by addressing the development of duration of long-term sickness absence in 
the Norwegian population. The vast majority of previous studies have focused on diagnoses 
that most frequently trigger sickness benefits, such as common mental disorders and 
musculoskeletal disorders. Our study has focused on all ICPC-2 diagnostic chapters, as well 
as on a group of physically overt diagnoses. By choosing diagnoses where one could expect a 
stabile or reduced duration of sickness absence, as in the case with our selected diagnoses, we 
aimed to access the potential implications of changes in thresholds for initiating, or continuing 
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a sickness absence episode. The robust increase in duration of sickness absence might be 
interpreted as a result of a possible increase in the threshold for terminating a sickness 
absence episode. Similarly the increase in prevalence of sickness absence episodes might 
reflect a lowered threshold for initiating sickness absence.  
Strengths and limitations 
The use of the FD-insurance registry is a major strength of this study. It contains 
diagnosis-specific information regarding the cause of individual sick-spells. Further, the 
routines for data- collection and storage are unchanged during the period of interest. Another 
apparent strength of FD-insurance is that it contains registrations of the total population in 
Norway. This allows us to bypass some of the classic challenges associated with survey-based 
research such as concerns in relation to attrition, generalizability, response rate, and social 
desirability. However, a possible limitation with FD-insurance is that the results rely on the 
accuracy of the registered diagnoses, which may be prone to errors. 
Since the aim of this study is to investigate the development of duration of sickness 
absence for full-time employees in the Norwegian population, individuals with income less 
than 3.5 B.a. were excluded. Due to this selection, it is not possible to generalize our results to 
part-time employees or employees earning less than 3.5 B.a.. A manifestation of this selection 
bias might be loss of information regarding the female work stock that more often work part-
time and loss of information regarding people employed in low-pay professions. It is also 
possible that we might have included well-paid part-time employees in our analysis. 
However, when targeting people earning more than 3.5 B.a., we capture more than 50 % of 
the Norwegian work stock, limiting the risk of a selection bias. A concern regarding such 
potential bias is reduced by our observation that when stratifying for age, gender and 
education, our results still indicate a robust increase in duration of sickness absence.  
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We hypothesized that our selected diagnoses occur with a stabile prevalence in the 
Norwegian population from 1994 to 2007. While we were not able to find reliable medical 
sources on the given prevalence for our selected diagnoses in Norway over the time period in 
question, based on our dataset we are able to infer that the prevalence of sickness absence 
episodes due to our selected diagnoses, are fairly stabile (Table 2). However, the 
cardiovascular group had a 4% increase in prevalence per calendar year. This increase in 
prevalence of cardiovascular related sickness absence might be a result of the national efforts 
in diagnosing and preventing cardiovascular incidences. However, we suggest that the 
increase in prevalence for the cardiovascular group might inoculate against a selection of 
more grave cases, as would be the case with a potential decrease in prevalence. 
It proved difficult to select diagnoses unaffected by advances in medical treatment 
procedures. Nevertheless, we suggest that potential medical advances should facilitate a 
reduction in the duration of sickness absence, hence contributing to the null-hypothesis, and 
strengthen rather than weaken our results. However, there is a risk that the medical advances 
have a paradoxical effect on the duration of sickness absence, by increasing the need for a 
prolonged recuperation period following more advanced medical procedures. The highest 
probability for confounding variables arises with regards to our selected diagnoses, where 
both the selected cardiovascular diagnoses [39] and appendicitis are subject to advances in 
surgical procedures. In addition, we also presume that the selected cardiovascular diagnoses 
are subject to advances in pharmacological treatment. We do not expect drastic improvement 
in treatment and prevention of the selected orthopedic diagnoses or concussion. However, the 
general increase in duration is observed for all ICPC-2 diagnostic chapters, limiting the risk of 
confounding variables.  
When selecting our diagnoses, they should typically be characterized by an abrupt 
onset, with a clear distinction between the time as “healthy” and “sick/injured”. Few ICPC-2 
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diagnoses fulfilled this criterion and the diagnoses that did (our selected diagnoses) still 
varied with regards to severity. However, the heterogeneity in severity is expected to remain 
the same during the studied period of time. 
Potential causes for the increase in duration of sickness absence 
During the studied period of time there is an increase in the populations mean age, 
percentage of women in the workforce and the percentage of employees with education 
exceeding high school (Table 1). As opposed to previous studies, our findings do not support 
the general trend where women drive the observed increases in sickness absence. On the 
contrary, we find that the increase in duration of sickness absence is more prominent for men 
compared to women. We find no plausible explanation for this finding.  
The increase in duration of sickness absence is highest in the group with education 
equivalent to elementary school. This finding could be explained by a potential 
overrepresentation of occupations with physical strain within this group, reflecting that 
prolonged sickness absence is increasingly necessary in physical occupations compared to 
academic occupations. However, the increase in employees with high education should 
outweigh the increase in duration of sickness absence caused by the low education group.  
The increase in duration of sickness absence observed in the low educational group 
could also be attributed to increased immigration during the period of interest, where 
segments of immigrant groups have lower education and higher levels of sickness absence 
compared to the mean population. However, these segments of immigrants compose a 
minority of the employed population in Norway [1], weakening this groups potential impact 
on the results. 
The increase in duration of sickness absence could be explained by an increase in the 
proportion of aging employees, and weakening of this cohort’s health or stamina. However, 
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the increase in duration of sickness absence is most prominent in the younger cohorts, 
compared to the cohorts aged > 49. In the group aged > 59, sickness absence decreases.  
Another explanation for the general increase in duration of sickness absence is based 
on a medical perspective. From this point of view, the observed development could be 
explained as a result of the populations’ ill health alone. It is possible, though not plausible, 
that the increase in duration of sickness absence is a reflection of a deterioration of public 
health in the Norwegian population, making prolonged sickness absence necessary. However, 
such an explanation is weakened by studies finding that the prevalence of e.g. 
musculoskeletal disorders remain stabile over time, while the sickness absence for these 
disorders increases during the same period of time [9, 40].  
Obviously, GPs play a crucial role in affecting the duration of sickness absence. As 
previously mentioned, the increase in duration of sickness absence, might be caused by a 
weakening of GPs gatekeeping role after the increased economical incentives following the 
implementation of the general practitioners scheme in 2001. However, the rise in duration of 
sickness absence is evident before the implementation of the general practitioners scheme, 
suggesting that this scheme is not the major driver of the observed development. Another 
explanation for the increase in duration of sickness absence might be increased difficulties for 
GPs when determining the optimal duration for a sickness absence episode. The previously 
mentioned public interventions in sickness absence management are presumed to affect not 
only the levels of sickness absence, but also the duration of sickness absence episodes. More 
specifically, the introduction of graded sickness absence in 2004 is assumed to drastically 
change the sick listing practices among GPs, reducing both the total prevalence of sickness 
absence and the duration of a sickness absence episode, highlighting the impact of GPs 
gatekeeping role [41]. 
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Another plausible explanation for the increase in duration of sickness absence, is 
related to trajectories in the Norwegian society. During the studied period there is a general 
increase in the percentage of employees in full-time employment in the studied population 
(Table 1). This increase coincides with the general decrease in unemployment in the general 
population. This expansion of the work stock might contribute to a ceiling effect, where the 
additive increase in the employed population leads to a potential inclusion of employees with 
ill health: employees that under different circumstances e.g. recession periods might not 
remain in paid work. However, disability rates have increased during the studied time period, 
indicating that individuals with marginalized health and low work ability are still recruited to 
more permanent disability benefits. Another hypothesis is that an increased need for 
employees leads to an associated increase in the employers’ demands of work efficiency and 
tempo. Combined, this might lead to increased work strain, and thus, expanding the risk for 
sickness absence of longer durations. 
The development in duration of sickness absence might also be understood as a result 
of factors residing outside of the sick listed individual. The increase in duration of sickness 
absence might be caused by an increasing imbalance between perceived control over 
perceived demands in different arenas of life. There might be changes in the employer’s 
preferences during the studied time period. With regards to a hypothesis where increased 
production and efficiency is valued at the workspace, it is possible that employees are urged 
to stay away from work when sick or disabled. Other circumstantial factors might also have 
changed, potentially making it increasingly more difficult to attend work with reduced work 
capacity during the studied period. The stabile prevalence of sickness absence, and the 
increase in duration of sickness absence might also be a result of increased workplace 
brutality, where work environments have grown more pathogenic or subject employees to 
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more physical or mental strain in 2007 compared with 1994. However, today there exists little 
support for this hypothesis [1]. 
The increase in duration of sickness absence might also be due to a gradually 
increasing and expanding moral hazard, where sickness absence is understood as a result of 
an individual’s rational choices and not simply ill health per se. In 2004 “graded sickness 
absence” was implemented to hamper the expanding growth in sickness absence levels. This 
public reform resulted in an evident reduction in duration of sickness absence, as illustrated in 
Figure 2. This public responsiveness to changes in public policy might be interpreted as a 
demonstration that levels of sickness absence and duration of sickness absence do not reflect 
the population’s ill health. However, if only emphasizing this point of view, one might fail to 
incorporate the fact that individuals might actually be sick, and sickness absence after a very 
serious illness or injury can hardly be argued to be a voluntary, rational choice.   
The residual explanation, -threshold issues and attitudes.  
We suggest that the results might indicate an attitudinal change with regards to the 
threshold for initiating and terminating a sickness absence episode. We initially presumed that 
this threshold was more dependent on personal attitudes when initiating sickness absence due 
to diffuse diagnoses, and less dependent on personal attitudes when initiating sickness absence 
due to overt diagnoses, similar to our selected diagnoses. Prior to our analysis we also 
assumed that attitudes play a fairly similar role when determining the appropriate threshold 
for terminating a sickness absence episode, for both diffuse and overt diagnoses. However, the 
increase in duration of sickness absence is observed for all diagnostic chapters in ICPC-2, and 
this does not provide support for our differentiation of the role of attitudes in sick listing 
practices for diffuse and overt diagnoses.  
The nature of our study design precludes our results from providing detailed 
explanations for the processes underlying the initiation of a given sick spell episode. 
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However, our results do provide indirect support of our hypothesis that the increase in 
duration of sickness absence and in the prevalence of sickness absence, might be affected by 
1) an increase in the threshold for terminating a sickness absence episode, and 2) a lowering 
of the threshold for initiating a sickness absence episode, respectively. If the increase in 
duration and prevalence of sickness absence is attributable to a change in the threshold for 
terminating and initiating a sickness absence episode, this change might originate at GPs, in 
the general society or at an individual level. 
Implications 
Long-term sickness absence increased by 1.5 calendar days per year from 1994 to 
2007. This increase is substantial, and if this development remains unaltered, the 
sustainability of the Norwegian welfare state might be jeopardized. At a societal level the 
increased public expenses are persuasive. From 1994 to 2004 public expenses in relation to 
sickness absence increased from NOK 10.442 billion to NOK 26.869 billion [35]. Hence the 
population’s sickness absence greatly affects the direction of public funding, in addition to the 
consequences associated with decreased individual contribution to the work stock [1]. 
Employers also suffer economic costs, either through the mandatory monetary expenses 
during the 16 days employer period, by expenses associated with hiring temporary employees, 
or through production loss [1, 17]. At a personal level, sickness absence has a wide range of 
implications on individual health, social life, lifestyle and emotional wellbeing [42]. Sickness 
absence is associated with decreased life quality, loss of social participation and loss of 
identity [1]. Sickness absence exceeding 8 calendar weeks greatly increases future risk of 
becoming recipients of more permanent disability pensions or being excluded from the 
workforce [1]. However, even after return to work, previous sickness absence increases the 
risk of decreased income [43] and reduced career possibilities [44]. Today there exists a 
robust empirical load and a strong scientific consensus that work is beneficial for both mental 
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and physical health [1, 45], and this has led to national efforts in reducing the high levels of 
sickness absence. On this note, national experts have highlighted a number of myths 
associated with sickness absence [1], myths that we presume might influence the population’s 
threshold with regards to initiation and termination of sickness absence episodes. By 
disproving typical misconceptions like “One has to be 100% healthy to be able to work” and 
“Work is bad for your health if you are ill” experts hope to affect peoples’ attitudes by 
elevating the public threshold for initiating and maintaining sickness absence.  
Conclusion 
We found a strong and consistent increase in duration of sickness absence of 1.5 
calendar days per calendar year from 1994 to 2007. Multiple causes have been suggested with 
a varying degree of support; some of the less plausible explanations attribute the increase in 
duration of sickness absence to changes in 1) demographics in the population, 2) health status 
in the population or 3) increased brutality in work environment. However, we find little 
support for these explanations.  
Plausible causes to the increase of the duration of sickness absence in the period might 
be 1) a weakening in gatekeeping among GPs, 2) an increase in moral hazard in the 
population and 3) changes in attitudes towards sickness absence. More specifically, we 
suggest that the increase in duration of sickness absence might be a result of 4) changes in the 
threshold for initiating and terminating a sickness absence episode. Further, this threshold is 
presumed to be dependent on, and subject to, gradual changes in attitudes in the population. 
We suggest that the observed development in duration of sickness absence is affected by an 
increase in the threshold for terminating a sickness absence episode, and a lowering of the 
threshold for initiating a sickness absence episode. 
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Table 1 - Characteristics of the studied population and the Norwegian population 
Year Mean age* 
Percentage 
of women in 
the 
workforce* 
Percentage with 
education 
equivalent to 
Bachelor's degree 
or higher* 
 Percentage 
of population 
in fulltime 
employment
* 
Total 
population of 
Norway** 
Percentage of 
unemployment 
in the Norwegian 
population** 
1994 39.3 39.6 % 30.0 % 28.0 % 4 324 815 5.20 % 
1995 39.5 39.7 % 30.0 % 29.1 % 4 348 410 4.70 % 
1996 39.8 39.9 % 31.0 % 30.1 % 4 369 957 4.20 % 
1997 40.0 40.1 % 32.0 % 31.2 % 4 392 714 3.30 % 
1998 40.2 40.4 % 32.0 % 32.4 % 4 417 599 2.40 % 
1999 40.5 40.9 % 33.0 % 33.1 % 4 445 329 2.60 % 
2000 40.9 41.2 % 33.0 % 33.3 % 4 478 497 2.70 % 
2001 41.2 41.5 % 34.0 % 33.5 % 4 503 436 2.70 % 
2002 41.6 41.9 % 35.0 % 33.5 % 4 524 066 3.20 % 
2003 42.0 42.2 % 36.0 % 33.0 % 4 552 252 3.90 % 
2004 42.4 42.3 % 37.0 % 32.6 % 4 577 457 3.90 % 
2005 42.7 42.4 % 38.0 % 32.8 % 4 606 363 3.50 % 
2006 42.8 42.7 % 38.0 % 33.7 % 4 640 219 2.60 % 
2007 42.9 42.9 % 39.0 % 34.5 % 4 681 134 1.90 % 
Footnotes: 
* Based on the studied population 
** Source: Statistics Norway  
Table 2 - Crude and population adjusted* prevalence of selected diagnoses and for all ICPC-2 diagnoses 
Year Prevalence type 
Selected 
orthopedic 
diagnoses 
Selected 
cardiovascular 
diagnoses 
Appendicitis Concussion All ICPC-2 diagnoses 
1994 Crude 10 987 1 012 494 365 158 584 Adjusted* 10 987 1 012 494 365 158 584 
1995 Crude 12 713 1 151 569 477 181 012 Adjusted* 12 168 1 102 545 457 173 249 
1996 Crude 13 815 1 255 577 530 204 821 Adjusted* 12 692 1 153 530 487 188 165 
1997 Crude 15 293 1 361 655 562 229 722 Adjusted* 13 482 1 200 577 495 202 521 
1998 Crude 16 415 1 507 713 536 257 362 Adjusted* 13 870 1 273 602 453 217 465 
1999 Crude 16 249 1 506 611 536 288 633 Adjusted* 13 355 1 238 502 441 237 232 
2000 Crude 17 657 1 716 626 596 321 934 Adjusted* 14 335 1 393 508 484 261 368 
2001 Crude 17 935 1 746 659 584 335 053 Adjusted* 14 364 1 398 528 468 268 339 
2002 Crude 17 986 1 865 628 563 343 310 Adjusted* 14 350 1 488 501 449 273 914 
2003 Crude 16 499 1 957 600 540 346 900 Adjusted* 13 307 1 578 484 436 279 778 
2004 Crude 15 491 1 825 548 541 308 380 Adjusted* 12 549 1 478 444 438 249 804 
2005 Crude 15 279 1 990 540 597 319 089 Adjusted* 12 237 1 594 432 478 255 559 
2006 Crude 15 934 2 072 495 662 333 141 Adjusted* 12 335 1 604 383 512 257 894 
2007 Crude 16 159 2 012 531 712 345 590 Adjusted* 12 106 1 507 398 533 258 917 
Calculated βГ Crude 271 80 -4 16 13 865 Adjusted* 13 44 -12 5 7 915 
Footnote:  
* =  Prevalence adjusted to size of the studied population in 1994.  
Г  =  Linear  regression  coefficient 
      Independent variable: Years 
      Dependent variable: Prevalence 
      β  =  increase  in  prevalence  per  year 
Table 3 - Increase  (β)*  in  duration  of    long-term sickness absence from 1994 to 2007, unstratified and stratified for gender, education and age 
Diagnoses 
 Number of 
sickness 
absence 
episodes in 
2007 
Mean duration of 
sickness absence 
in 2007 
Unstratified 
(β)*   Men  (β)* Women  (β)* 
Elementary 
school  (β)* 
High School 
(β)* 
Bachelor's 
degree or higher 
(β)* 
18-29  (β)* 30-39  (β)* 40-49  (β)* 50-59  (β)* >59  (β)* 
Selected orthopedic 
diagnoses 16 159 64.1 1.4 1.2 1.5 1.7 1.5 1.0 1.0 1.2 1.2 1.2 0.5 
Selected 
cardiovascular 
diagnoses 
2 012 165.0 -0.1 -0.3 0.3 0.7 0.3 -0.7 -3.7 0.3 0.2 -0.4 -2.3 
Appendicitis 531 21.6 0.7 0.6 0.8 1.0 0.5 0.7 0.3 0.4 0.9 0.8 0.9 
Concussion 712 78.1 2.6 2.5 2.6 3.5 2.1 2.0 1.5 2.9 2.0 2.7 5.1 
All ICPC-2 diagnoses 345 590 82.6 1.5 1.7 1.4 1.9 1.7 1.3 1.3 1.5 1.3 1.1 -0.8 
A General and 
Unspecified 20 036 74.1 2.6 2.7 2.6 2.8 2.7 2.6 2.1 2.5 2.7 2.3 1.0 
B Blood** 1 534 121.8 1.8 1.4 2.0 2.2 1.8 1.7 0.6 0.6 1.0 2.1 -0.1 
D Digestive 16 071 64.3 1.3 1.5 1.0 1.4 1.2 1.6 0.9 1.0 1.2 1.1 0.4 
F Eye 2 513 60.3 0.8 1.1 0.5 1.0 0.9 0.8 0.7 0.8 0.2 0.8 -0.1 
H Ear 2 620 80.2 2.0 2.2 1.9 2.4 1.4 1.8 0.4 1.8 1.3 1.1 1.1 
K Cardiovascular 15 312 104.2 0.1 0.0 0.8 0.6 -0.1 0.6 0.6 0.7 -0.1 -0.7 -3.2 
L Musculosceletal 141 323 85.3 1.7 1.8 1.4 2.1 1.9 1.1 1.3 1.7 1.5 1.2 -0.7 
N Neurological 16 353 91.0 -0.1 -0.2 0.1 0.2 0.2 -0.5 0.4 0.4 -0.5 -1.0 -3.4 
P Psychological 60 006 98.6 1.4 1.2 1.5 1.9 1.3 1.1 1.3 1.4 1.3 1.1 -1.1 
R Respiratory 22 693 40.8 1.0 1.1 1.0 1.3 1.0 1.2 0.4 0.9 0.8 0.9 -0.1 
 S Skin 7 895 55.8 1.0 1.1 0.8 1.3 0.9 1.1 0.8 1.2 0.9 1.1 -0.2 
T Endocrine*** 5 752 92.8 0.6 1.0 0.4 1.0 0.1 0.9 0.7 0.0 0.4 0.6 -2.0 
U Urological 2 488 65.8 0.9 1.9 0.1 1.2 0.8 0.8 1.1 1.1 0.5 0.5 -1.0 
W Pregnancy**** 23 157 73.4 1.2 1.9 1.1 1.9 1.6 1.1 1.3 1.1 1.3 1.8 5.3 
X Female, genital 6 134 86.8 1.6 - 1.6 1.8 1.3 1.9 0.8 0.8 1.0 1.6 0.2 
Y Male Genital 1 518 80.0 2.2 1.6 - 3.0 1.7 1.7 2.0 1.1 1.0 2.4 0.9 
Z Social Problems 69 80.4 3.9 4.2 3.8 4.0 2.4 4.4 2.3 3.0 4.3 5.0 3.3 
Footnotes: 
* Dependent variable: Years 
Independent variable: Mean duration of sickness absence episodes 
β  =  Increased calendar days per calendar year 
**   Chapter B Blood, Blood Forming Organs and Immune Mechanisms 
*** Chapter T Endocrine/Metabolic and Nutritional 
**** Chapter W Pregnancy, Child Bearing, Family Planning 
Footnote: 
*   Sickness absence exceeding 16 days, hence reimbursed by            
the National Sickness Insurance Scheme  
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Figure 1 - Duration of sickness absence* for selected diagnoses and all ICPC-2 diagnoses 
Selected orthopedic diagnoses
Selected cardiovascular diagnoses
Appendicitis
Concussion
All ICPC-2 diagnoses
020
40
60
80
100
120
140
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
M
ea
n 
re
im
bu
rs
ed
 ca
le
nd
ar
 d
ay
s*
 
Figure 2 - Mean duration of sickness absence* for all ICPC-2 diagnostic chapters 
A General and Unspecified
B Blood, Blood Forming Organs
and Immune Mechanisms
D Digestive
F Eye
H Ear
K Cardiovascular
L Musculosceletal
N Neurological
P Psychological
R Respiratory
 S Skin
T Endocrine/Metabolic and
Nutritional
U Urological
W Pregnancy, Child Bearing,
Family Planning
X Female, genital
Y Male Genital
Z Social Problems
Footnote: 
* Sickness absence exceeding 16 days, hence reimbursed by the National 
Sickness Insurance Scheme  
Footnote: 
* Adjusted for population size 
y = 3019.1x + 128876 
y = 3931.2x + 56797 
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Figure 3 - Development of prevalence* of sickness absence episodes per calendar year, divided into sickness absence 
episodes with duration over and under-, eight calendar weeks 
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Over calendar eight weeks
1 
 
Appendix I: 
BMC Public Health Instructions For Authors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Instructions  for  authors  
Research  article 
Criteria | Submission process | Preparing main manuscript text | Preparing illustrations and 
figures | Preparing tables | Preparing additional files | Style and language  
Assistance with the process of manuscript preparation and submission is available from BioMed 
Central customer support team. See 'About this journal' for information about policies and the 
refereeing process. We also provide a collection of links to useful tools and resources for 
scientific authors on our page. 
Criteria 
Research articles should report on original primary research, but may report on systematic 
reviews of published research provided they adhere to the appropriate reporting guidelines which 
are detailed in 'About this journal'. 
Submission process 
Manuscripts must be submitted by one of the authors of the manuscript, and should not be 
submitted by anyone on their behalf. The submitting author takes responsibility for the article 
during submission and peer review.  
Please note that BMC Public Health levies an article-processing charge on all accepted Research 
articles, Case reports, Database articles, Debates, Software articles, Study protocols and 
Technical advance articles articles; if the submitting author's institution is a BioMed Central 
member the cost of the article-processing charge may be covered by the membership (see About 
page for detail). Please note that the membership is only automatically recognised on submission 
if the submitting author is based at the member institution. 
To facilitate rapid publication and to minimize administrative costs, BMC Public Health accepts 
only online submission.  
Files can be submitted as a batch, or one by one. The submission process can be interrupted at 
any time; when users return to the site, they can carry on where they left off. 
See below for examples of word processor and graphics file formats that can be accepted for the 
main manuscript document by the online submission system. Additional files of any type, such as 
movies, animations, or original data files, can also be submitted as part of the manuscript. 
During submission you will be asked to provide a cover letter. Use this to explain why your 
manuscript should be published in the journal, to elaborate on any issues relating to our editorial 
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policies in the 'About BMC Public Health' page, and to declare any potential competing interests. 
You will be also asked to provide the contact details (including email addresses) of potential peer 
reviewers for your manuscript. These should be experts in their field, who will be able to provide 
an objective assessment of the manuscript. Any suggested peer reviewers should not have 
published with any of the authors of the manuscript within the past five years, should not be 
current collaborators, and should not be members of the same research institution. Suggested 
reviewers will be considered alongside potential reviewers recommended by the Editorial team, 
Editorial Advisors, Section Editors and Associate Editors.  
Assistance with the process of manuscript preparation and submission is available from BioMed 
Central customer support team. 
We also provide a collection of links to useful tools and resources for scientific authors on our 
Useful Tools page. 
File formats 
The following word processor file formats are acceptable for the main manuscript document: 
 Microsoft Word (version 2 and above) 
 Rich text format (RTF) 
 Portable document format (PDF) 
 TeX/LaTeX (use BioMed Central's TeX template) 
 DeVice Independent format (DVI) 
Users of other word processing packages should save or convert their files to RTF before 
uploading. Many free tools are available which ease this process. 
TeX/LaTeX users: We recommend using BioMed Central's TeX template and BibTeX stylefile. 
If you use this standard format, you can submit your manuscript in TeX format. If you have used 
another template for your manuscript, or if you do not wish to use BibTeX, then please submit 
your manuscript as a DVI file. We do not recommend converting to RTF. 
Note that figures must be submitted as separate image files, not as part of the submitted 
manuscript file. 
Preparing main manuscript text 
General guidelines of the journal's style and language are given below. 
Overview of manuscript sections for Research article 
Manuscripts for Research article articles submitted to BMC Public Health should be divided into 
the following sections (in this order): 
 Title page 
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 Abstract 
 Keywords 
 Background  
 Methods  
 Results and discussion 
 Conclusions 
 List of abbreviations used (if any) 
 Competing interests 
 Authors' contributions 
 Authors' information  
 Acknowledgements 
 Endnotes 
 References 
 Illustrations and figures (if any) 
 Tables and captions 
 Preparing additional files 
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates 
cited in the manuscript should be provided, in square brackets and include the corresponding 
database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, 
GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116]. 
The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database 
(EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data 
Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-
Prot). 
You can download a template (Mac and Windows compatible; Microsoft Word 98/2000) for your 
article. 
For reporting standards please see the information in the About section. 
Title page 
The title page should: 
 provide the title of the article 
 list the full names, institutional addresses and email addresses for all authors 
 indicate the corresponding author 
Please note: 
 the title should include the study design, for example "A versus B in the treatment of C: a 
randomized controlled trial X is a risk factor for Y: a case control study" 
 abbreviations within the title should be avoided 
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Abstract 
The Abstract of the manuscript should not exceed 350 words and must be structured into separate 
sections: Background, the context and purpose of the study; Methods, how the study was 
performed and statistical tests used; Results, the main findings; Conclusions, brief summary and 
potential implications. Please minimize the use of abbreviations and do not cite references in the 
abstract. Trial registration, if your Research article articles reports the results of a controlled 
health care intervention, please list your trial registry, along with the unique identifying number 
(e.g. Trial registration: Current Controlled Trials ISRCTN73824458). Please note that there 
should be no space between the letters and numbers of your trial registration number. We 
recommend manuscripts that report randomized controlled trials follow the CONSORT extension 
for abstracts. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background  
The Background section should be written in a way that is accessible to researchers without 
specialist knowledge in that area and must clearly state - and, if helpful, illustrate - the 
background to the research and its aims. Reports of clinical research should, where appropriate, 
include a summary of a search of the literature to indicate why this study was necessary and what 
it aimed to contribute to the field. The section should end with a brief statement of what is being 
reported in the article. 
Methods 
The methods section should include the design of the study, the setting, the type of participants or 
materials involved, a clear description of all interventions and comparisons, and the type of 
analysis used, including a power calculation if appropriate. Generic drug names should generally 
be used. When proprietary brands are used in research, include the brand names in parentheses in 
the Methods section. 
For studies involving human participants a statement detailing ethical approval and consent 
should be included in the methods section. For further details of the journal's editorial policies 
and ethical guidelines see 'About this journal'. 
For further details of the journal's data-release policy, see the policy section in 'About this 
journal'. 
Results and discussion 
The Results and discussion may be combined into a single section or presented separately. 
Results of statistical analysis should include, where appropriate, relative and absolute risks or risk 
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reductions, and confidence intervals. The Results and discussion sections may also be broken into 
subsections with short, informative headings. 
Conclusions 
This should state clearly the main conclusions of the research and give a clear explanation of 
their importance and relevance. Summary illustrations may be included. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and a list of 
abbreviations can be provided, which should precede the competing interests and authors' 
contributions. 
Competing interests 
A competing interest exists when your interpretation of data or presentation of information may 
be influenced by your personal or financial relationship with other people or organizations. 
Authors must disclose any financial competing interests; they should also reveal any non-
financial competing interests that may cause them embarrassment were they to become public 
after the publication of the manuscript. 
Authors are required to complete a declaration of competing interests. All competing interests 
that are declared will be listed at the end of published articles. Where an author gives no 
competing interests, the listing will read 'The author(s) declare that they have no competing 
interests'. 
When completing your declaration, please consider the following questions: 
Financial competing interests 
 In the past five years have you received reimbursements, fees, funding, or salary from an 
organization that may in any way gain or lose financially from the publication of this 
manuscript, either now or in the future? Is such an organization financing this manuscript 
(including the article-processing charge)? If so, please specify. 
 Do you hold any stocks or shares in an organization that may in any way gain or lose 
financially from the publication of this manuscript, either now or in the future? If so, 
please specify. 
 Do you hold or are you currently applying for any patents relating to the content of the 
manuscript? Have you received reimbursements, fees, funding, or salary from an 
organization that holds or has applied for patents relating to the content of the 
manuscript? If so, please specify. 
 Do you have any other financial competing interests? If so, please specify. 
Non-financial competing interests  
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Are there any non-financial competing interests (political, personal, religious, ideological, 
academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, 
please specify. 
If you are unsure as to whether you, or one your co-authors, has a competing interest please 
discuss it with the editorial office. 
Authors' contributions 
In order to give appropriate credit to each author of a paper, the individual contributions of 
authors to the manuscript should be specified in this section. 
An 'author' is generally considered to be someone who has made substantive intellectual 
contributions to a published study. To qualify as an author one should 1) have made substantial 
contributions to conception and design, or acquisition of data, or analysis and interpretation of 
data; 2) have been involved in drafting the manuscript or revising it critically for important 
intellectual content; and 3) have given final approval of the version to be published. Each author 
should have participated sufficiently in the work to take public responsibility for appropriate 
portions of the content. Acquisition of funding, collection of data, or general supervision of the 
research group, alone, does not justify authorship. 
We suggest the following kind of format (please use initials to refer to each author's 
contribution): AB carried out the molecular genetic studies, participated in the sequence 
alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in the 
sequence alignment. ES participated in the design of the study and performed the statistical 
analysis. FG conceived of the study, and participated in its design and coordination and helped to 
draft the manuscript. All authors read and approved the final manuscript.  
All contributors who do not meet the criteria for authorship should be listed in an 
acknowledgements section. Examples of those who might be acknowledged include a person who 
provided purely technical help, writing assistance, or a department chair who provided only 
general support. 
Authors' information 
You may choose to use this section to include any relevant information about the author(s) that 
may aid the reader's interpretation of the article, and understand the standpoint of the author(s). 
This may include details about the authors' qualifications, current positions they hold at 
institutions or societies, or any other relevant background information. Please refer to authors 
using their initials. Note this section should not be used to describe any competing interests. 
Acknowledgements 
Please acknowledge anyone who contributed towards the article by making substantial 
contributions to conception, design, acquisition of data, or analysis and interpretation of data, or 
who was involved in drafting the manuscript or revising it critically for important intellectual 
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content, but who does not meet the criteria for authorship. Please also include the source(s) of 
funding for each author, and for the manuscript preparation. Authors must describe the role of the 
funding body, if any, in design, in the collection, analysis, and interpretation of data; in the 
writing of the manuscript; and in the decision to submit the manuscript for publication. Please 
also acknowledge anyone who contributed materials essential for the study. If a language editor 
has made significant revision of the manuscript, we recommend that you acknowledge the editor 
by name, where possible.  
The role of a scientific (medical) writer must be included in the acknowledgements section, 
including their source(s) of funding. We suggest wording such as 'We thank Jane Doe who 
provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.' 
Authors should obtain permission to acknowledge from all those mentioned in the 
Acknowledgements section. 
Endnotes 
Endnotes should be designated within the text using a superscript lowercase letter and all notes 
(along with their corresponding letter) should be included in the Endnotes section. Please format 
this section in a paragraph rather than a list. 
References 
All references, including URLs, must be numbered consecutively, in square brackets, in the order 
in which they are cited in the text, followed by any in tables or legends. Each reference must have 
an individual reference number. Please avoid excessive referencing. If automatic numbering 
systems are used, the reference numbers must be finalized and the bibliography must be fully 
formatted before submission. 
Only articles, datasets and abstracts that have been published or are in press, or are available 
through public e-print/preprint servers, may be cited; unpublished abstracts, unpublished data and 
personal communications should not be included in the reference list, but may be included in the 
text and referred to as "unpublished observations" or "personal communications" giving the 
names of the involved researchers. Obtaining permission to quote personal communications and 
unpublished data from the cited colleagues is the responsibility of the author. Footnotes are not 
allowed, but endnotes are permitted. Journal abbreviations follow Index Medicus/MEDLINE. 
Citations in the reference list should include all named authors, up to the first 30 before adding 'et 
al.'. 
Any in press articles cited within the references and necessary for the reviewers' assessment of 
the manuscript should be made available if requested by the editorial office. 
Style files are available for use with popular bibliographic management software: 
 BibTeX 
 EndNote style file 
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 Reference Manager 
 Zotero 
Examples of the BMC Public Health reference style are shown below. Please ensure that the 
reference style is followed precisely; if the references are not in the correct style they may have to 
be retyped and carefully proofread.  
All web links and URLs, including links to the authors' own websites, should be given a 
reference number and included in the reference list rather than within the text of the manuscript. 
They should be provided in full, including both the title of the site and the URL, in the following 
format: The Mouse Tumor Biology Database 
[http://tumor.informatics.jax.org/mtbwi/index.do]. If an author or group of authors can clearly be 
associated with a web link, such as for weblogs, then they should be included in the reference. 
Examples of the BMC Public Health reference style 
 
Article within a journal 
Koonin EV, Altschul SF, Bork P: BRCA1 protein products: functional motifs. Nat Genet 
1996, 13:266-267. 
Article within a journal supplement 
Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: Analysis and assessment of ab initio 
three-dimensional prediction, secondary structure, and contacts prediction. Proteins 1999, 
43(Suppl 3):149-170. 
In press article 
Kharitonov SA, Barnes PJ: Clinical aspects of exhaled nitric oxide. Eur Respir J, in press. 
Published abstract 
Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN: Mesenchymal cells, 
stromal derived factor-1 and rheumatoid arthritis [abstract]. Arthritis Rheum 1999, 42:s250. 
Article within conference proceedings 
Jones X: Zeolites and synthetic mechanisms. In Proceedings of the First National Conference 
on Porous Sieves: 27-30 June 1996; Baltimore. Edited by Smith Y. Stoneham: Butterworth-
Heinemann; 1996:16-27. 
Book chapter, or article within a book 
Schnepf E: From prey via endosymbiont to plastids: comparative studies in dinoflagellates. 
In Origins of Plastids. Volume 2. 2nd edition. Edited by Lewin RA. New York: Chapman and 
Hall; 1993:53-76. 
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Whole issue of journal 
Ponder B, Johnston S, Chodosh L (Eds): Innovative oncology. In Breast Cancer Res 1998, 10:1-
72. 
Whole conference proceedings 
Smith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; 
Baltimore. Stoneham: Butterworth-Heinemann; 1996. 
Complete book 
Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970. 
Monograph or book in a series 
Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured Human Cells and Tissues. 
Edited by Harris TJR. New York: Academic Press; 1995:54-56. [Stoner G (Series Editor): 
Methods and Perspectives in Cell Biology, vol 1.] 
Book with institutional author 
Advisory Committee on Genetic Modification: Annual Report. London; 1999. 
PhD thesis 
Kohavi R: Wrappers for performance enhancement and oblivious decision graphs. PhD 
thesis. Stanford University, Computer Science Department; 1995. 
Link / URL 
The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do] 
Link / URL with author(s) 
Neylon C: Open Research Computation: an ordinary journal with extraordinary aims. 
[http://blogs.openaccesscentral.com/blogs/bmcblog/entry/open_research_computation_an_ordina
ry] 
Dataset with persistent identifier 
Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; Peng, Y; Dong, S-S; Liu, T-F; Jiang, S; Ramachandran, 
S; Liu, C-M; Jing, H-C (2011): Genome data from sweet and grain sorghum (Sorghum bicolor). 
GigaScience. http://dx.doi.org/10.5524/100012. 
Preparing illustrations and figures 
Illustrations should be provided as separate files, not embedded in the text file. Each figure 
should include a single illustration and should fit on a single page in portrait format. If a figure 
consists of separate parts, it is important that a single composite illustration file be submitted 
which contains all parts of the figure. There is no charge for the use of color figures. 
Please read our figure preparation guidelines for detailed instructions on maximising the quality 
of your figures. 
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Formats 
The following file formats can be accepted: 
 EPS (preferred format for diagrams) 
 PDF (also especially suitable for diagrams) 
 TIFF 
 PNG (preferred format for photos or images) 
 Microsoft Word (version 5 and above; figures must be a single page) 
 PowerPoint (figures must be a single page) 
 JPEG 
 BMP 
Figure legends 
The legends should be included in the main manuscript text file at the end of the document, rather 
than being a part of the figure file. For each figure, the following information should be provided: 
Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure 
(maximum 15 words); detailed legend, up to 300 words. 
Please note that it is the responsibility of the author(s) to obtain permission from the 
copyright holder to reproduce figures or tables that have previously been published 
elsewhere. 
Preparing a personal cover page 
If you wish to do so, you may submit an image which, in the event of publication, will be used to 
create a cover page for the PDF version of your article. The cover page will also display the 
journal logo, article title and citation details. The image may either be a figure from your 
manuscript or another relevant image. You must have permission from the copyright to reproduce 
the image. Images that do not meet our requirements will not be used. 
Images must be 300dpi and 155mm square (1831 x 1831 pixels for a raster image). 
Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for photographs and screen 
dumps), JPEG, BMP, DOC, PPT, CDX, TGF (ISIS/Draw). 
Preparing tables 
Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 
etc.). Tables should also have a title (above the table) that summarizes the whole table; it should 
be no longer than 15 words. Detailed legends may then follow, but they should be concise. Tables 
should always be cited in text in consecutive numerical order. 
Smaller tables considered to be integral to the manuscript can be pasted into the end of the 
document text file, in A4 portrait or landscape format. These will be typeset and displayed in the 
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final published form of the article. Such tables should be formatted using the 'Table object' in a 
word processing program to ensure that columns of data are kept aligned when the file is sent 
electronically for review; this will not always be the case if columns are generated by simply 
using tabs to separate text. Columns and rows of data should be made visibly distinct by ensuring 
that the borders of each cell display as black lines. Commas should not be used to indicate 
numerical values. Color and shading may not be used; parts of the table can be highlighted using 
symbols or bold text, the meaning of which should be explained in a table legend. Tables should 
not be embedded as figures or spreadsheet files. 
Larger datasets or tables too wide for a portrait page can be uploaded separately as additional 
files. Additional files will not be displayed in the final, laid-out PDF of the article, but a link will 
be provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls) or 
comma separated values (.csv). As with all files, please use the standard file extensions. 
Preparing additional files 
Although BMC Public Health does not restrict the length and quantity of data included in an 
article, there may still be occasions where an author wishes to provide data sets, tables, movie 
files, or other information as additional files. Results that would otherwise be indicated as "data 
not shown" can and should be included as additional files. Since many weblinks and URLs 
rapidly become broken, BMC Public Health requires that all supplementary data are included as 
additional files rather than as a link to your own website. These files can be uploaded using the 
'Additional Material files' button in the manuscript submission tool. 
The maximum file size for additional files is 20 MB each, and files will be virus-scanned on 
submission. 
Additional files will be linked to the final published article in the form supplied by the author, but 
will not be displayed within the article. They will be made available in exactly the same form as 
originally provided by the authors. 
If additional material is provided, please list the following information in a separate section of the 
manuscript text, immediately following the tables (if any): 
 File name (e.g. Additional file 1) 
 File format including the three-letter file extension (including name and a URL of an 
appropriate viewer if format is unusual) 
 Title of data 
 Description of data 
Additional files should be named "Additional file 1" and so on and should be referenced 
explicitly by file name within the body of the article, e.g. 'An additional movie file shows this in 
more detail [see Additional file 1]'. 
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Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should be viewable 
using free or widely available tools. The following are examples of suitable formats. 
 Additional documentation  
o PDF (Adode Acrobat) 
 Animations  
o SWF (Shockwave Flash) 
 Movies  
o MOV (QuickTime) 
o MPG (MPEG) 
 Tabular data  
o XLS (Excel Spreadsheet) 
o CSV (Comma separated values) 
As with figure files, files should be given the standard file extensions. This is especially 
important for Macintosh users, since the Mac OS does not enforce the use of standard extensions. 
Please also make sure that each additional file is a single table, figure or movie (please do not 
upload linked worksheets or PDF files larger than one sheet). 
Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way that they will be 
browsable from within the full text HTML version of the article. In order to do this, please follow 
these instructions: 
1. Create a folder containing a starting file called index.html (or index.htm) in the root. 
2. Put all files necessary for viewing the mini-website within the folder, or sub-folders. 
3. Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" 
or "http://yourdomain.net/images/picture.jpg" or "C:\Documents and 
Settings\username\My Documents\mini-website\images\picture.jpg") and no link is 
longer than 255 characters. 
4. Access the index.html file and browse around the mini-website, to ensure that the most 
commonly used browsers (Internet Explorer and Firefox) are able to view all parts of the 
mini-website without problems, it is ideal to check this on a different machine. 
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html 
is in the root of the ZIP, and that the file has .zip extension, then submit as an additional 
file with your article. 
Style and language 
General 
Currently, BMC Public Health can only accept manuscripts written in English. Spelling should be 
US English or British English, but not a mixture. 
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There is no explicit limit on the length of articles submitted, but authors are encouraged to be 
concise. There is also no restriction on the number of figures, tables or additional files that can be 
included with each article online. Figures and tables should be numbered in the order in which 
they are referred to in the text. Authors should include all relevant supporting data with each 
article. 
BMC Public Health will not edit submitted manuscripts for style or language; reviewers may 
advise rejection of a manuscript if it is compromised by grammatical errors. Authors are advised 
to write clearly and simply, and to have their article checked by colleagues before submission. In-
house copyediting will be minimal. Non-native speakers of English may choose to make use of a 
copyediting service. 
Language editing 
For authors who wish to have the language in their manuscript edited by a native-English speaker 
with scientific expertise, BioMed Central recommends Edanz. BioMed Central has arranged a 
10% discount to the fee charged to BioMed Central authors by Edanz. Use of an editing service is 
neither a requirement nor a guarantee of acceptance for publication. Please contact Edanz directly 
to make arrangements for editing, and for pricing and payment details. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, please visit our 
page on Writing titles and abstracts for scientific articles. 
Tim Albert has produced for BioMed Central a list of tips for writing a scientific manuscript. 
American Scientist also provides a list of resources for science writing. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined when first used 
and a list of abbreviations can be provided following the main manuscript text. 
Typography 
 Please use double line spacing. 
 Type the text unjustified, without hyphenating words at line breaks. 
 Use hard returns only to end headings and paragraphs, not to rearrange lines. 
 Capitalize only the first word, and proper nouns, in the title. 
 All pages should be numbered. 
 Use the BMC Public Health reference format. 
 Footnotes are not allowed, but endnotes are permitted. 
 Please do not format the text in multiple columns. 
 Greek and other special characters may be included. If you are unable to reproduce a 
particular special character, please type out the name of the symbol in full. Please ensure 
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that all special characters used are embedded in the text, otherwise they will be lost 
during conversion to PDF. 
Units 
SI units should be used throughout (liter and molar are permitted, however).
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